Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095706 · ClinicalTrials.gov registry record · Phase 1
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
A Phase 1 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00095706 is a Phase 1 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 50 participants.
The verdict
NCT00095706, a Phase 1 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.
Interventions
- DRUG Bevacizumab (drug), Herceptin (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095706
The ClinicalTrials.gov registry entry for NCT00095706 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab (drug), Herceptin (drug) is the first listed.
NCT00095706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095706 about?
NCT00095706 is a clinical study titled "Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)". The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.
What is the current status of trial NCT00095706?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2003-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00095706?
The interventions under investigation include: Bevacizumab (drug), Herceptin (drug) (DRUG).
Who is sponsoring clinical trial NCT00095706?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.